Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Nobukazu Fujimoto's publication output changed over time?
ScholarIQpublication output · 2005–2022
Output grew0% over the shown period — from 2 works in 2005 to 2 in 2022.
2
1
1
1
1
1
1
1
2
200520062009201020112019202020212022
What are the most-cited papers on Nobukazu Fujimoto?
ScholarIQmost cited works
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas, Arnaud Scherpereel, Anna K. Nowak, Nobukazu Fujimoto, Solange Peters, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, Thierry Jahan, Scott Antonia, Youssef Oulkhouir, Yolanda Bautista, Robin Cornelissen, Laurent Greillier, Francesco Grossi, Dariusz M. Kowalski, Jerónimo Rafael Rodríguez‐Cid, Praveen Aanur, Abderrahim Oukessou, Christine Baudelet, Gérard Zalcman
The Lancet. 20211,212 CitationsOPEN ACCESS
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Solange Peters, Arnaud Scherpereel, Robin Cornelissen, Youssef Oulkhouir, Laurent Greillier, Kaplan Ma, Thomas Talbot, I. Monnet, Sandrine Hiret, P. Baas, Anna K. Nowak, Nobukazu Fujimoto, Anne S. Tsao, Aaron S. Mansfield, Sanjay Popat, X. Zhang, Nan Hu, David Balli, Thomas Spires, Gérard Zalcman
Annals of Oncology. 2022266 CitationsOPEN ACCESS
Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)
Morihito Okada, Takashi Kijima, Keisuke Aoe, Terufumi Kato, Nobukazu Fujimoto, Kazuhiko Nakagawa, Yuichiro Takeda, Toyoaki Hida, Kuninobu Kanai, Fumio Imamura, Satoshi Oizumi, Toshiaki Takahashi, Mitsuhiro Takenoyama, Hiroshi Tanaka, Jun Hirano, Yoshinobu Namba, Yuichiro Ohe
Clinical Cancer Research. 2019237 Citations
Identification of Epigenetic Aberrant Promoter Methylation in Serum DNA Is Useful for Early Detection of Lung Cancer
Keiichi Fujiwara, Nobukazu Fujimoto, Masahiro Tabata, Kenji Nishii, Keitaro Matsuo, Katsuyuki Hotta, Toshiyuki Kozuki, Motoi Aoe, Katsuyuki Kiura, Hiroshi Ueoka, Mitsune Tanimoto
Clinical Cancer Research. 2005203 CitationsOPEN ACCESS
High Expression of Ligands for Chemokine Receptor CXCR2 in Alveolar Epithelial Neoplasia Induced by Oncogenic Kras
Marie Wislez, Nobukazu Fujimoto, Julie Izzo, Amy E. Hanna, Dianna D. Cody, Robert R. Langley, Hongli Tang, Marie D. Burdick, Mitsuo Sato, John D. Minna, Li Mao, Ignacio I. Wistuba, Robert M. Strieter, Jonathan M. Kurie
Cancer Research. 2006162 Citations
Related on ScholarIQ
Inserm
Institution
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paper
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Paper
Clinical Efficacy and Safety of Nivolumab: Results of a <u>M</u> ulticenter, Op <u>e</u> n-label, Single-a <u>r</u> m, Japanese Phase II study in Mal <u>i</u> gnant Pleural Meso <u>t</u> helioma (MERIT)
Paper
Identification of Epigenetic Aberrant Promoter Methylation in Serum DNA Is Useful for Early Detection of Lung Cancer
Paper
High Expression of Ligands for Chemokine Receptor CXCR2 in Alveolar Epithelial Neoplasia Induced by Oncogenic Kras
Paper